FY2017 Earnings Forecast for Gilead Sciences, Inc. (GILD) Issued By Jefferies Group
Gilead Sciences, Inc. (NASDAQ:GILD) – Analysts at Jefferies Group decreased their FY2017 earnings estimates for Gilead Sciences in a research note issued to investors on Wednesday. Jefferies Group analyst M. Yee now forecasts that the biopharmaceutical company will earn $8.21 per share for the year, down from their previous estimate of $8.34. Jefferies Group has a “Positive” rating on the stock. Jefferies Group also issued estimates for Gilead Sciences’ Q1 2018 earnings at $1.58 EPS, Q2 2018 earnings at $1.54 EPS, Q3 2018 earnings at $1.49 EPS, Q4 2018 earnings at $1.52 EPS and FY2018 earnings at $6.15 EPS.
Several other research firms have also commented on GILD. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price on the stock in a report on Wednesday, September 6th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, July 27th. ValuEngine lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 13th. Finally, Bank of America Corporation dropped their target price on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating on the stock in a report on Wednesday. Twelve investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and an average price target of $85.43.
WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/06/fy2017-earnings-forecast-for-gilead-sciences-inc-gild-issued-by-jefferies-group.html.
Gilead Sciences (GILD) opened at 83.51 on Friday. The stock’s 50 day moving average price is $80.69 and its 200-day moving average price is $71.56. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27. The stock has a market capitalization of $109.06 billion, a PE ratio of 9.07 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the previous year, the firm earned $3.08 EPS. The business’s quarterly revenue was down 8.2% on a year-over-year basis.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.49%. Gilead Sciences’s payout ratio is presently 22.58%.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $242,749,648.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the completion of the sale, the executive vice president now directly owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders sold 486,819 shares of company stock valued at $39,298,919 over the last ninety days. Insiders own 1.30% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of GILD. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. grew its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Penserra Capital Management LLC grew its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. Webster Bank N. A. grew its stake in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares in the last quarter. Finally, American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences in the first quarter valued at $143,000. 73.99% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.